Evidence method
Level · gp.fundamentals.debt_to_revenue
74.48% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ADPT · Dec 31, 2024
Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-25-030913General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.05% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-53.20% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
5.10% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
4.72% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
59.72% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-90.83% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
57.53% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
29.96% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.74%
- Current
- 2.05%
- Delta
- 1.31%
- Previous
- -58.29%
- Current
- -53.20%
- Delta
- 5.08%
- Previous
- 22.46%
- Current
- 5.10%
- Delta
- -17.36%
- Previous
- 25.75%
- Current
- 4.72%
- Delta
- -21.03%
- Previous
- 64.11%
- Current
- 59.72%
- Delta
- -4.38%
- Previous
- -70.27%
- Current
- -90.83%
- Delta
- -20.56%
- Previous
- 52.04%
- Current
- 57.53%
- Delta
- 5.49%
- Previous
- 29.12%
- Current
- 29.96%
- Delta
- 0.84%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ADPT Fundamental State →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT CAPEX_INTENSITY_INCREASED →Transitioned To · ADPT CASH_GENERATION_INCREASED →Transitioned To · ADPT GROWTH_DECREASED →Transitioned To · ADPT INVENTORY_PRESSURE_DECREASED →Transitioned To · ADPT MARGIN_DECREASED →Transitioned To · ADPT PROFITABILITY_DECREASED →Transitioned To · ADPT R_AND_D_INTENSITY_INCREASED →Transitioned To · ADPT SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.